Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval

Conducting Meta-Analyses inRwith themetaforPackage

(2015) Wolfgang Viechtbauer   Journal of Statistical Software

Hairy cell leukemia: Update on molecular profiling and therapeutic advances

(2014) Michael R. Grever et al.   BLOOD REVIEWS

New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs

(2014) J. M. Jurgensmeier et al.   CLINICAL CANCER RESEARCH

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

(2014) Keith T Flaherty et al.   LANCET ONCOLOGY

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2013) Alessandro Liberati   ANNALS OF INTERNAL MEDICINE

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes

(2013) H. Henary et al.   ANNALS OF ONCOLOGY

Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs

(2013) D. L. Jardim et al.   CLINICAL CANCER RESEARCH

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer

(2013) Luc Friboulet et al.   NEW ENGLAND JOURNAL OF MEDICINE

First FDA Authorization for Next-Generation Sequencer

(2013) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy

(2012) Sarah B. Fisher et al.   CANCER

Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009

(2012) F. Janku et al.   CLINICAL CANCER RESEARCH

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

(2012) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy

(2012) J. R. Westin et al.   MOLECULAR CANCER THERAPEUTICS

Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment

(2012) Margaret K. Callahan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

How to obtain the P value from a confidence interval

(2011) D. G. Altman et al.   BMJ-British Medical Journal

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial

(2009) Apostolia-Maria Tsimberidou et al.   JOURNAL OF CLINICAL ONCOLOGY

Translation of the Philadelphia chromosome into therapy for CML

(2008) B. J. Druker   BLOOD